Loading...

BCR-ABL突变检测指导下的达沙替尼治疗伊马替尼耐药的慢性髓性白血病疗效分析

OBJECTIVE: To evaluate the efficiency of dasatinib as the second- or third-line tyrosine kinase inhibitor (TKI) in imatinib-resistant patients with chronic myeloid leukemia (CML) based on BCR-ABL mutation detection. METHODS: 122 CML patients received dasatinib treatment, including 83 with imatinib-r...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Zhonghua Xue Ye Xue Za Zhi
Format: Artigo
Sprog:Inglês
Udgivet: Editorial office of Chinese Journal of Hematology 2016
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7342298/
https://ncbi.nlm.nih.gov/pubmed/26876246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.01.002
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!